A recent poll shows that half of Americans say theyll get a COVID-19 vaccination when it becomes available.
Only about half of Americans in a recent poll say theyll get a COVID-19 vaccination when it becomes available, according to a recent study. A Pittsburgh-based immunology expert said he hopes they change their minds.
The Associated Press-NORC Center for Public Affairs Research found that if a vaccine against coronavirus becomes available to the public, only about half of those polled said they plan to get vaccinated; 20 percent said they will not; and about a third of those polled are not sure.
I advocate vaccines. They clearly have been shown to be safe in multiple studies, said Dr. William Klimstra, a professor of immunology at the University of Pittsburgh, during a Facebook Live discussion with Auditor General Eugene DePasquale. You just have to basically accept when you have essentially universal consensus among people who should know about something, in this case that vaccines are safe.
The top reason folks said they would be less inclined to get the vaccine is because of safety, particularly fear of potential side effects of the vaccine.
Seven out of 10 people polled who do not plan to get the vaccine said they are concerned about the side effects with nearly half being concerned with contracting the coronavirus. About one in three said they are not concerned about getting seriously ill from the virus.
Dr. William Klimstra, who works in the Department of Immunology and the Microbiology and Molecular Genetics Department at the University of Pittsburgh, is a member of the Center for Virus Research. An advocate of vaccines, he has been involved in several previous vaccine designs.
Klimstra spoke with Pennsylvania Auditor General Eugene DePasquale during a Facebook Live session on Wednesday and said the anti-vaccine rhetoric on social media and parts of the internet should not be accepted by anybody who thinks about this critically.
Were in an environment right now where long-standing excepted truths are being challenged through social media and other things, he said. Ive read a lot of the anti-vaccine literature and things that are on the internet, and people seem to feel Big Pharma is promoting these things and then scientists because they get grants. They have been compromised because of Big Pharma.
Klimstra said that vaccines are advocated by doctors, because theyre proven to be safe and effective.
I advocate vaccines. They clearly have been shown to be safe in multiple studies, he said. You just have to basically accept when you have essentially universal consensus among people who should know about something, in this case that vaccines are safe.
One argument against vaccines is that it causes autism, which Klimstra says, has been debunked completely.
Safety is scientists foremost priority when it comes to vaccine creation, Klimstra said. This is why its taking months to create a COVID-19 vaccine, he said.
The reason that its taking longer a frustratingly long time to get a coronavirus vaccine in the marketplace is because of the safety testing, he said.
Klimstra said people can have adverse reactions to vaccines. But its just vanishingly small with vaccines. And the links to autism are just not held up by science, he said.
Hundreds of millions of lives have been saved because of vaccines, Klimstra stressed.
Looking back, historically vaccines are one of the most productive and important medical technologies that have ever been used, he said.
Similarly to using masks, Klimstra said its not just about keeping yourself safe vaccines help prevent transmission of the virus.
The Associated Press-NORC Center for Public Affairs Research poll showed the top reasons for the nearly half of folks who said they would get a coronavirus vaccine are about protecting them, their family and their communities from the virus.
Among those polled, four out of five said they believe a vaccine is "an important criteria" for reopening, while nearly half say it's essential. About one-third say a vaccine is not essential for reopening.
Klimstra said vaccines are proven to be effective, calling them standard medical treatments.
Weve eliminated smallpox. Polio is almost eliminated, measles was nearly eliminated until people stopped taking the vaccine, he said. You wouldnt go to the doctor and not have a treatment for a medical condition where the treatment was nearly completely safe and worked a high percentage of the time. You wouldnt do that.
And thats what a vaccine is a standard medical treatment that saves lives. You just have to listen to people who should know about the issue.
For anti-vaxxers and those who arent convinced to get the coronavirus vaccine when it eventually becomes available, Klimstra said he hopes they will change their minds.
Its a critical issue both for themselves and for other people, he said.
Klimstra called it having a protective attitude and a positive community attitude.
These vaccines will be safe. I can guarantee that, he said. Given the technologies that will be utilized, they will be safe.
See the original post here:
To vax or not to vax: Pitt scientist discusses importance of vaccines - The Times
- The future of immunology - Johnson & Johnson - March 5th, 2025 [March 5th, 2025]
- Immunotherapys Sweet Future: Wrapping up AACR IO 2025 With Glyco-immunology - American Association for Cancer Research (AACR) - March 5th, 2025 [March 5th, 2025]
- J&J receives three CHMP recommendations for immunology and oncology indications - PMLiVE - March 5th, 2025 [March 5th, 2025]
- Greater Austin Allergy, Asthma & Immunology now open in the Shops at the Galleria - Community Impact - March 5th, 2025 [March 5th, 2025]
- As dengue spreads, researchers discover a clue to fighting the virus - La Jolla Institute for Immunology - February 25th, 2025 [February 25th, 2025]
- Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress - Business... - February 25th, 2025 [February 25th, 2025]
- PhD candidate Jesse Lehman receives Kirschstein Award to study immunology - UMass Medical School - February 25th, 2025 [February 25th, 2025]
- Cross-priming in cancer immunology and immunotherapy - Nature.com - February 3rd, 2025 [February 3rd, 2025]
- Sanofi Happy To Spend To Hit Immunology Top Spot - News & Insights - February 3rd, 2025 [February 3rd, 2025]
- The Converging Therapeutic Landscape of Oncology and Immunology: Accelerating Innovation in Biotech - MedCity News - January 23rd, 2025 [January 23rd, 2025]
- VC Firm Foresite Capital Dishes on Biotech Innovation in China, Opportunities in Immunology - MedCity News - January 23rd, 2025 [January 23rd, 2025]
- Immunology - The Scientist - January 23rd, 2025 [January 23rd, 2025]
- Immunology Startup Ouro Sets Out With $120M for Drugs That Reset the Immune System - MedCity News - January 15th, 2025 [January 15th, 2025]
- Scipher Medicine and Atropos Health Partner to Accelerate Precision Medicine and Expand the Immunology Multimodal Network - Business Wire - December 23rd, 2024 [December 23rd, 2024]
- AbbVie to expand immunology pipeline with $200m Nimble Therapeutics acquisition - PMLiVE - December 23rd, 2024 [December 23rd, 2024]
- Sir Gustav Nossal Professor of Immunology to honour giant of Australian science - Walter and Eliza Hall Institute of Medical Research - December 9th, 2024 [December 9th, 2024]
- Research Assistant in Immunology - Surrey, United Kingdom job with UNIVERSITY OF SURREY | 384335 - Times Higher Education - November 28th, 2024 [November 28th, 2024]
- Reflecting on Pioneering organoids and 3D cell cultures for animal and human health - British Society for Immunology | - November 28th, 2024 [November 28th, 2024]
- Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET - Business Wire - November 20th, 2024 [November 20th, 2024]
- TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development - Business Wire - November 20th, 2024 [November 20th, 2024]
- Discovering Solutions for Long COVID: A T-Cell Immunology Breakthrough - Infection Control Today - November 20th, 2024 [November 20th, 2024]
- Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET IPH6501 - The Bakersfield Californian - November 20th, 2024 [November 20th, 2024]
- Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of... - November 20th, 2024 [November 20th, 2024]
- What it's like in allergy and immunology: Shadowing Dr. Fraser - American Medical Association - November 12th, 2024 [November 12th, 2024]
- Dr. Naba Sharif Elected President of the New Jersey Allergy Asthma and Immunology Society - Newswire - November 12th, 2024 [November 12th, 2024]
- Department of Microbiology and Immunology Named a National Milestones Program - Stony Brook News - October 26th, 2024 [October 26th, 2024]
- Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting - businesswire.com - October 26th, 2024 [October 26th, 2024]
- Remembering immunology educator, researcher Tom McDonald, PhD - University of Nebraska Medical Center - October 13th, 2024 [October 13th, 2024]
- Systems immunology approaches to study T cells in health and disease - Nature.com - October 13th, 2024 [October 13th, 2024]
- Leading the charge to discover answers in immunology - The University of Arizona - October 2nd, 2024 [October 2nd, 2024]
- New mouse models offer valuable window into COVID-19 infection - La Jolla Institute for Immunology - October 2nd, 2024 [October 2nd, 2024]
- Wide-Moat AbbVie Poised for Growth, Driven by Innovation in Immunology Beyond Humira - Morningstar - October 2nd, 2024 [October 2nd, 2024]
- Lilly's immunology unit scores another FDA nod with eczema treatment Ebglyss - FiercePharma - September 23rd, 2024 [September 23rd, 2024]
- Huang Named Head Of Pathology And Immunology - Mirage News - September 15th, 2024 [September 15th, 2024]
- Huang named head of pathology & immunology - Washington University School of Medicine in St. Louis - September 15th, 2024 [September 15th, 2024]
- Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit - Yahoo Finance - September 15th, 2024 [September 15th, 2024]
- Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit - StockTitan - September 15th, 2024 [September 15th, 2024]
- UCLA receives $120 million from Alya and Gary Michelson for new California Institute for Immunology and Immunotherapy - UCLA Newsroom - September 2nd, 2024 [September 2nd, 2024]
- Boosting vaccines for the elderly with 'hyperactivators' - Boston Children's Answers - Boston Children's Discoveries - June 27th, 2024 [June 27th, 2024]
- Immunologists Want You to Know These Dust Mite Allergy Facts - Yahoo Lifestyle UK - June 27th, 2024 [June 27th, 2024]
- How Ragon Institute's new building aids its mission Harvard Gazette - Harvard Gazette - June 27th, 2024 [June 27th, 2024]
- Insights into CRS and NPs: Visual and Bibliometric Analysis - Physician's Weekly - June 27th, 2024 [June 27th, 2024]
- Biogen joins immunology wave with $1.15 billion acquisition of HI-Bio - STAT - May 24th, 2024 [May 24th, 2024]
- Biogen Buys Desired Growth In Immunology With $1.15bn Hi-Bio Deal - Scrip - May 24th, 2024 [May 24th, 2024]
- Biogen Boosts Immunology Portfolio with $1.8 Billion Acquisition of HI-Bio - BioPharm International - May 24th, 2024 [May 24th, 2024]
- Owkin Unveils AI-Driven Oncology and Immunology Pipeline, In-Licenses Best-in-Class Asset OKN4395 - Yahoo Finance - May 24th, 2024 [May 24th, 2024]
- Biogen to expand immunology and rare disease portfolio with $1.8bn HI-Bio acquisition - PMLiVE - May 24th, 2024 [May 24th, 2024]
- Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress - Business Wire - May 24th, 2024 [May 24th, 2024]
- Biogen to buy Human Immunology Biosciences in deal worth up to $1.8B - MM+M Online - May 24th, 2024 [May 24th, 2024]
- COVID-19 Re-Vaccinations Elicit Neutralizing Antibodies Against Future Variants - Technology Networks - May 24th, 2024 [May 24th, 2024]
- HIV Vaccine Candidate Induces Broadly Neutralizing Antibodies in Humans - Technology Networks - May 24th, 2024 [May 24th, 2024]
- Pasteur Fiocruz Center on Immunology and Immunotherapy is inaugurated in Cear - Fiocruz - May 24th, 2024 [May 24th, 2024]
- Biogen to buy Human Immunology Biosciences in up to $1.8 billion deal - Marketscreener.com - May 24th, 2024 [May 24th, 2024]
- Fellow Focus in Four: Marat Kribis, MD, Rheumatology, Allergy and Immunology - Yale School of Medicine - April 15th, 2024 [April 15th, 2024]
- Long COVID Can Now Be Detected in the Blood - Technology Networks - April 15th, 2024 [April 15th, 2024]
- Rimjhim Agarwal selected as Major Symposium speaker at the American Association of Immunologists ... - La Jolla Institute for Immunology - March 29th, 2024 [March 29th, 2024]
- Seeking new horizons: Where innovators find opportunities in a fast-changing immunology landscape - IQVIA - March 29th, 2024 [March 29th, 2024]
- Researchers identify new way to inhibit immune cells that drive allergic asthma - EurekAlert - March 29th, 2024 [March 29th, 2024]
- Innovation in Oncology and Cancer Immunology Research - Boehringer Ingelheim - March 29th, 2024 [March 29th, 2024]
- Measles outbreaks show the risk of under-vaccination | News | Harvard T.H. Chan School of Public Health - HSPH News - March 29th, 2024 [March 29th, 2024]
- Immunology-oncology ELISA Kits Market to Witness a Healthy Growth by 2030 - WhaTech - March 29th, 2024 [March 29th, 2024]
- Spring Allergy Season Is Getting Worse. Here's What to Know. - The New York Times - March 29th, 2024 [March 29th, 2024]
- Multiple sclerosis has distinct subtypes, study finds, pointing to different treatments - STAT - March 29th, 2024 [March 29th, 2024]
- Researchers identify viable vaccine targets for hepatitis C infections - News-Medical.Net - March 29th, 2024 [March 29th, 2024]
- Three research projects awarded funding from the Immunology Institute Pilot Project program - University of Alabama at Birmingham - February 29th, 2024 [February 29th, 2024]
- Deal Watch: AbbVie Adds To Immunology Pipeline Through Deal With OSE - Scrip - February 29th, 2024 [February 29th, 2024]
- AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology ... - PR Newswire - February 29th, 2024 [February 29th, 2024]
- Integrating single-cell multi-omics and prior biological knowledge for a functional characterization of the immune system - Nature.com - February 29th, 2024 [February 29th, 2024]
- Renowned immunologist and four-decade UAB researcher Max Cooper, M.D., will deliver this year's Marx Lecture - University of Alabama at Birmingham - February 29th, 2024 [February 29th, 2024]
- Inactivation of TGF- signaling in CAR-T cells | Cellular & Molecular Immunology - Nature.com - February 29th, 2024 [February 29th, 2024]
- Babies use their immune system differently but efficiently | Cornell Chronicle - Cornell Chronicle - February 29th, 2024 [February 29th, 2024]
- Antibody reduces allergic reactions to multiple foods in NIH clinical trial - National Institutes of Health (NIH) (.gov) - February 29th, 2024 [February 29th, 2024]
- Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its ... - GlobeNewswire - February 21st, 2024 [February 21st, 2024]
- Theratechnologies announces publication in Frontiers in Immunology on TH1902 - TipRanks.com - TipRanks - February 21st, 2024 [February 21st, 2024]
- Smoking has long-term effects on the immune system - Institut Pasteur - February 21st, 2024 [February 21st, 2024]
- Spring Allergies Attack More Than Just Your Nose - ACAAI Public Website - American College of Allergy Asthma and Immunology - February 21st, 2024 [February 21st, 2024]
- Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel ... - GlobeNewswire - February 21st, 2024 [February 21st, 2024]
- Shikhar Mehrotra named co-leader of Cancer Biology and Immunology research program at MUSC Hollings - The Cancer Letter - January 27th, 2024 [January 27th, 2024]
- Gut Microbiome Benefits of Breast Milk Revealed in Mouse Study - Technology Networks - January 27th, 2024 [January 27th, 2024]
- Research on Immunological Diseases Launches with Hungarian Participation - Hungary Today - January 27th, 2024 [January 27th, 2024]